Paper · 2026 · Open access

Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy

SK. Abdul Muzeer, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi Pagadala, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi Pagadala

Zenodo (CERN European Organization for Nuclear Research) · Published 12 February 2026 · DOI 10.5281/zenodo.18621852

Open full textCite this paper

In brief

“Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy” is a 2026 paper by SK. Abdul Muzeer, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi Pagadala and 3 co-authors, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
0
Authors
4

Abstract

The pharmacogenomics represents a transformative approach in modern medicine, combining genomic science with pharmacology to personalize drug therapy. By identifying genetic variations that influence drug absorption, metabolism and response pharmacogenomics enables the optimization of treatment outcomes while minimizing adverse effects. This field bridges the gap between genetic diversity and therapeutic precision, allowing clinicians to tailor drug selection and dosage for individual patients. Recent advances in genomic sequencing bioinformatics, and also molecular diagnostics have accelerated the clinical application of pharmacogenomics across oncology, cardiology, and psychiatry and However, challenges such as limited population-specific data, ethical considerations, and integration into the routine healthcare systems persist The future of pharmacogenomics lies in large-scale genomic databases, artificial intelligence-driven prediction models, and global collaboration to achieve true individualized and equitable healthcare. At its also conceptual core, pharmacogenomics functions as a genetic navigation system for clinicians. By decoding the patient genome, it provides predictive maps indicating the safest therapeutic routes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Pagadala, S. A. M. J. T. S. D. R. V. R. T. S., SaiKrishna, J. T., Raviteja, D., & Pagadala, V. R. T. S. (2026). Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18621852

MLA 9

Pagadala, SK. Abdul Muzeer, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi, et al. “Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.18621852.

Chicago

Pagadala, SK. Abdul Muzeer, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi, J. T. SaiKrishna, D. Raviteja, and V R Teja Sruthi Pagadala. 2026. “Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18621852.

Harvard

Pagadala, S. A. M. J. T. S. D. R. V. R. T. S. et al. (2026) ‘Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.18621852.

IEEE

S. A. M. J. T. S. D. R. V. R. T. S. Pagadala, J. T. SaiKrishna, D. Raviteja, and V. R. T. S. Pagadala, “Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.18621852.

BibTeX

@article{pagadala2026pharmacogenomics,
  title     = {{Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy}},
  author    = {Pagadala, SK. Abdul Muzeer, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi and SaiKrishna, J. T. and Raviteja, D. and Pagadala, V R Teja Sruthi},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.18621852},
  url       = {https://doi.org/10.5281/zenodo.18621852}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • individualized drug therapy
  • genetic variation
  • drug metabolism
  • adverse drug reactions
  • pharmacogenetic testing
  • genomic databases
  • artificial intelligence prediction models

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Pagadala, S. A. M. J. T. S. D. R. V. R. T. S., SaiKrishna, J. T., Raviteja, D., & Pagadala, V. R. T. S. (2026). Pharmacogenomics the Genetic Blue Print for Personalized Drug Therapy. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18621852

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Zenodo (CERN European Organization for Nuclear Research): sign in and open the full text from this page.

Who wrote this paper?

SK. Abdul Muzeer, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi Pagadala, J. T. SaiKrishna, D. Raviteja, V R Teja Sruthi Pagadala.

What is the DOI of this paper?

10.5281/zenodo.18621852, permanently at https://doi.org/10.5281/zenodo.18621852. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.